Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

Otros documentos

SML3083

Sigma-Aldrich

Palovarotene

≥98% (HPLC)

Sinónimos:

(E)-4-(2-(3-((1H-Pyrazol-1-yl)methyl)-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid, 4-[(1E)-2-[5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-3-(1H-pyrazol-1-ylmethyl)-2-naphthalenyl]ethenyl]benzoic acid, 4-[(E)-2-(5,5,8,8-Tetramethyl-3-pyrzol-1-ylmethyl-5,6,7,8-tetrahydro-naphthalen-2-yl)vinyl]benzoic acid, R 667, R-667, R667, RG 667, RG-667, RG667, RO 3300074, RO-3300074, RO3300074

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C27H30N2O2
Número de CAS:
410528-02-8
Peso molecular:
414.54
MDL number:
MFCD10565968
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

CC1(C2=CC(CN3C=CC=N3)=C(/C=C/C4=CC=C(C=C4)C(O)=O)C=C2C(C)(CC1)C)C

InChI

1S/C27H30N2O2/c1-26(2)12-13-27(3,4)24-17-22(18-29-15-5-14-28-29)21(16-23(24)26)11-8-19-6-9-20(10-7-19)25(30)31/h5-11,14-17H,12-13,18H2,1-4H3,(H,30,31)/b11-8+

InChI key

YTFHCXIPDIHOIA-DHZHZOJOSA-N

Biochem/physiol Actions

Palovarotene is an orally active, selective retinoic acid receptor gamma (RARγ) agonist that reduces heterotopic ossification (HO) in cultures (15-300 nM) and in murine and rat fibrodysplasia ossificans progressiva (FOP) models in vivo (1 mg/kg rat, 0.27-2.49 mg/kg mouse or 15-100 μg/mouse via daily p.o.).

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Sayantani Sinha et al.
Bone, 90, 59-68 (2016-02-20)
Heterotopic ossification (HO) consists of ectopic cartilage and bone formation following severe trauma or invasive surgeries, and a genetic form of it characterizes patients with Fibrodysplasia Ossificans Progressiva (FOP). Recent mouse studies showed that HO was significantly inhibited by systemic
Benjamin M Wheatley et al.
Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 36(4), 1135-1144 (2017-09-30)
Heterotopic ossification (HO) develops in the extremities of wounded service members and is common in the setting of high-energy penetrating injuries and blast-related amputations. No safe and effective prophylaxis modality has been identified for this patient population. Palovarotene has been
Sonia A Garcia et al.
International journal of molecular sciences, 21(8) (2020-04-17)
Osteochondromas are cartilage-capped growths located proximate to the physis that can cause skeletal deformities, pain, limited motion, and neurovascular impingement. Previous studies have demonstrated retinoic acid receptor gamma (RARγ) agonists to inhibit ectopic endochondral ossification, therefore we hypothesize that RARγ

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico